The cost effectiveness of budesonide in severe asthmatics aged one to three years
The cost effectiveness of budesonide in severe asthmatics aged one to three years
The cost effectiveness of budesonide treatment was determined in a 6-month randomised, double blind, placebo controlled study of 40 asthmatic children aged one to three years with persistent asthma symptoms despite bronchodilator therapy. Budesonide produced a mean (± sd) of 62 (54) symptom-free days compared with 38 (36) for placebo. Direct costs were reduced with budesonide by fewer doctor consultations and fewer hospital admissions for shorter periods. Indirect cost benefits occurred through reductions in the days lost from work by parents and days lost from playgroup by the child because of asthma. Total costs/patient/year for a budesonide- and placebo-treated child were £1397.83 and £1891.43, respectively. The marginal cost effectiveness ratio was -£6.33 in favour of budesonide. Budesonide effectively reduces asthma symptoms compared to placebo and the additional drug costs are substantially offset by a reduced use of healthcare services and reduced indirect costs to childrens' families.
Asthma, Budesonide, Children, Cost effectiveness
127-134
Connett, G.J.
55d5676c-90d8-46bf-a508-62eded276516
Lenney, W.
16ca6fdd-ab7a-4462-8215-1c6ef991cf1c
McConchie, S.M.
1c72d082-c51f-4e76-96b0-ae34346a3e05
1993
Connett, G.J.
55d5676c-90d8-46bf-a508-62eded276516
Lenney, W.
16ca6fdd-ab7a-4462-8215-1c6ef991cf1c
McConchie, S.M.
1c72d082-c51f-4e76-96b0-ae34346a3e05
Connett, G.J., Lenney, W. and McConchie, S.M.
(1993)
The cost effectiveness of budesonide in severe asthmatics aged one to three years.
British Journal of Medical Economics, 6, .
Abstract
The cost effectiveness of budesonide treatment was determined in a 6-month randomised, double blind, placebo controlled study of 40 asthmatic children aged one to three years with persistent asthma symptoms despite bronchodilator therapy. Budesonide produced a mean (± sd) of 62 (54) symptom-free days compared with 38 (36) for placebo. Direct costs were reduced with budesonide by fewer doctor consultations and fewer hospital admissions for shorter periods. Indirect cost benefits occurred through reductions in the days lost from work by parents and days lost from playgroup by the child because of asthma. Total costs/patient/year for a budesonide- and placebo-treated child were £1397.83 and £1891.43, respectively. The marginal cost effectiveness ratio was -£6.33 in favour of budesonide. Budesonide effectively reduces asthma symptoms compared to placebo and the additional drug costs are substantially offset by a reduced use of healthcare services and reduced indirect costs to childrens' families.
This record has no associated files available for download.
More information
Published date: 1993
Keywords:
Asthma, Budesonide, Children, Cost effectiveness
Identifiers
Local EPrints ID: 420674
URI: http://eprints.soton.ac.uk/id/eprint/420674
ISSN: 0962-1423
PURE UUID: 7358facb-b15a-4067-ab2d-9f203d18f192
Catalogue record
Date deposited: 11 May 2018 16:30
Last modified: 15 Jun 2022 01:51
Export record
Contributors
Author:
G.J. Connett
Author:
W. Lenney
Author:
S.M. McConchie
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics